Fadi Chalhoub
Geriatric Medicine · Jacksonville, FLNPI 1568451557
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.4%), travel and lodging and gifts — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Pfizer at 36.7% of the total. Reporting peaked in 2019 at $3,087 and has fallen 96.3% since, to $114 in 2025. Among geriatric medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 45 payments — averaging $121.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$2K
- AstraZeneca$981
- Medtronic$639
- Alnylam Pharmaceuticals Inc.$634
- Boehringer Ingelheim$284
- Amgen$241
- plus $684 from 6 others
Across 3,112 payments — averaging $3814.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$8.6M
- Alnylam Pharmaceuticals Inc.$1.8M
- Modernatx, Inc.$862K
- GSK$311K
- Dermavant Sciences, Inc.$187K
- AstraZeneca$93K
- plus $17K from 4 others
What the payments were for
- Travel & lodging$2,58247%
- Food & beverage$2,86352%
- Gifts$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 6 | $2,003 |
| AstraZeneca | 10 | $981 |
| Medtronic | 12 | $639 |
| Alnylam Pharmaceuticals Inc. | 4 | $634 |
| Boehringer Ingelheim | 3 | $284 |
| Amgen(2 entities) | 2 | $241 |
| Otsuka America Pharmaceutical, Inc. | 2 | $218 |
| Philips North America LLC | 2 | $157 |
| Vapotherm Inc | 1 | $123 |
| Biosense Webster, Inc. | 1 | $114 |
| Abbott | 1 | $60 |
| Novartis | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,465 in reported general payments places this provider in the 95th percentile of 305 geriatric medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 525 | $160,874 |
| NuplazidPimavanserin Tartrate | 11 | $38,704 |
| JanuviaSitagliptin Phosphate | 94 | $27,773 |
| TradjentaLinagliptin | 75 | $20,653 |
| TrulicityDulaglutide | 28 | $19,716 |
| GemtesaVibegron | 75 | $19,348 |
| XareltoRivaroxaban | 53 | $17,641 |
| LokelmaSodium Zirconium Cyclosilicate | 17 | $14,505 |
| OzempicSemaglutide | 13 | $14,389 |
| EntrestoSacubitril/Valsartan | 35 | $12,396 |
| JardianceEmpagliflozin | 39 | $12,357 |
| LinzessLinaclotide | 19 | $11,782 |
| Atorvastatin Calcium | 561 | $9,953 |
| Gabapentin | 387 | $9,258 |
| Spiriva RespimatTiotropium Bromide | 16 | $8,880 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $2,003 | $160,874525 claims |
| Boehringer IngelheimTradjenta, Jardiance, Spiriva Respimat | $284 | $41,890130 claims |
| AstraZenecaLokelma, Farxiga | $981 | $17,94729 claims |
| NovartisEntresto | $12 | $12,39635 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 305 geriatric medicine providers in Florida.
Other geriatric medicine in Jacksonville
- Regina BielawskiJacksonville$4K
- Samira KhazravanJacksonville$3K
- Sherif El-SalawyJacksonville$2K
- Malcolm FraserBrooksville$359K
- Andrew ScanameoTallahassee$172K
- Naushira PandyaDavie$145K
- Rosemary LairdViera$64K
- Jonathan AppelbaumMonticello$59K
- John PotomskiMelbourne$31K
- Valeria Baldivieso HurtadoWinter Park$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.